Search

Author/Creator Stangier, Joachim

1. An open-label study of the pharmacokinetics and pharmacodynamics of dabigatran etexilate 150 mg once daily in Caucasian patients with moderate renal impairment undergoing primary unilateral elective total knee or hip replacement surgery. Issue 144 (August 2016)

Authors:
Eriksson, Bengt I.; Mikuska, Zsolt; Feuring, Martin; Amiral, Jean; Haertter, Sebastian; Stangier, Joachim; Nehmiz, Gerhard; Weitz, Jeffrey I.
Journal:
Thrombosis research
Issue:
Issue 144(2016)
Page Start:
158
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

2. An open-label study of the pharmacokinetics and pharmacodynamics of dabigatran etexilate 150 mg once daily in Caucasian patients with moderate renal impairment undergoing primary unilateral elective total knee or hip replacement surgery. Issue 144 (August 2016)

Authors:
Eriksson, Bengt I.; Mikuska, Zsolt; Feuring, Martin; Amiral, Jean; Haertter, Sebastian; Stangier, Joachim; Nehmiz, Gerhard; Weitz, Jeffrey I.
Journal:
Thrombosis research
Issue:
Issue 144(2016)
Page Start:
158
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

3. Evaluation of the immunogenicity of the dabigatran reversal agent idarucizumab during Phase I studies. (6th April 2017)

Authors:
Norris, Stephen; Ramael, Steven; Ikushima, Ippei; Haazen, Wouter; Harada, Akiko; Moschetti, Viktoria; Imazu, Susumu; Reilly, Paul A.; Lang, Benjamin; Stangier, Joachim; Glund, Stephan
Journal:
British journal of clinical pharmacology
Issue:
Volume 83:Number 8(2017)
Page Start:
1815
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

6. Pharmacokinetics of idarucizumab and its target dabigatran in patients requiring urgent reversal of the anticoagulant effect of dabigatran. (18th June 2019)

Authors:
Glund, Stephan; Coble, Kelly; Gansser, Dietmar; Stangier, Joachim; Hoermann, Karin; Pollack, Charles V.; Reilly, Paul
Journal:
Journal of thrombosis and haemostasis
Issue:
Volume 17:Number 8(2019)
Page Start:
1319
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

7. Safety, pharmacokinetics and pharmacodynamics of idarucizumab, a specific dabigatran reversal agent in healthy Japanese volunteers: a randomized study. Issue 2 (5th August 2017)

Authors:
Yasaka, Masahiro; Ikushima, Ippei; Harada, Akiko; Imazu, Susumu; Taniguchi, Atsushi; Norris, Stephen; Gansser, Dietmar; Stangier, Joachim; Schmohl, Michael; Reilly, Paul A.
Journal:
Research and practice in thrombosis and haemostasis
Issue:
Volume 1:Issue 2(2017)
Page Start:
202
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

8. Safety, tolerability, and efficacy of idarucizumab for the reversal of the anticoagulant effect of dabigatran in healthy male volunteers: a randomised, placebo-controlled, double-blind phase 1 trial. Issue 9994 (15th August 2015)

Authors:
Glund, Stephan; Stangier, Joachim; Schmohl, Michael; Gansser, Dietmar; Norris, Stephen; van Ryn, Joanne; Lang, Benjamin; Ramael, Steven; Moschetti, Viktoria; Gruenenfelder, Fredrik; Reilly, Paul; Kreuzer, Jörg
Journal:
Lancet
Issue:
Volume 386:Issue 9994(2015)
Page Start:
680
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗